Send articles on social media
‘Truvada’ proven effective in preventing HIV and AIDSis finally released in Korea.
According to the Ministry of Food and Drug Safety on the 19th, multinational pharmaceutical company Gilead Sciences Korea’s HIV infection treatment ‘Truvada’has been approved for use in the prevention of AIDS. Hankook Ilbosaid
This is the first time that a non-vaccine drug has been recognized for its disease-preventing effect in Korea.
Truvada has been approved for use only in the treatment of AIDS in Korea, but from the 13th, efficacy and effect (indications) were added so that it can be used to reduce the risk of infection before exposure to HIV.
As a result, high-risk groups whose sexual partners are HIV-infected or who have sex in a community or social network with many HIV-infected people can receive Truvada as a preventive treatment.
However, the problem is that if Truvada is prescribed for the purpose of preventing AIDS, the cost burden is considerable. The price of one Truvada tablet is 13,720 won, and if you take it every day for one year, the price alone is 5,011,450 won.
The World Health Organization (WHO) last year Truvada has been designated as a drug for the prevention of AIDS.
Truvada was used in clinical trials conducted in high-risk groups in several countries. It has already been proven to be very effective in preventing HIV. If you take your medicine every day according to the medication guidance, Prevents HIV infection by up to 99%is known to do In the US, France, and South Africa, ‘Truvada’ has been used as an HIV prevention drug for 4-5 years.
The number of new HIV infections worldwide is on the decline. According to global HIV data released by UNAIDs, there were 1.8 million new cases of HIV in 2016, down 11% from 1.9 million in 2010.
On the other hand, in Korea, the number of infected continues to increase. Center for Disease ControlAccording to the report, there were 1,199 new cases of HIV reported in Korea in 2016 (1062 Koreans, 137 foreigners), up 4% from 1152 in 2015. This is a 43% increase from 837 in 2010.